Lund University Hospital
Clinical trials sponsored by Lund University Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Tailored timing of radioactive therapy may boost tumor control in NETs Results expected Oct 2026 (estimated)
- Triple-Drug chemo blitz aims to boost stomach cancer survival Results expected Nov 2026 (estimated)
- Can blood and skin markers predict lymphoma outcomes? Results expected Apr 2027 (estimated)
- Cheaper jaw implants might work just as well with smart planning Results expected Jun 2027 (estimated)
-
Triple-Drug chemo blitz aims to boost stomach cancer survival
Disease control OngoingThis phase 2 trial tests whether adding a third chemotherapy drug (irinotecan) to the standard two-drug regimen (FOLFOX) improves outcomes for patients with resectable stomach or gastroesophageal junction cancer. 60 participants receive the three-drug combo before and after surge…
Phase 2 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:23 UTC
-
Could adding capecitabine boost chemo success in Triple-Negative breast cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug capecitabine to standard chemotherapy improves outcomes for people with early triple-negative breast cancer. The study involves 325 participants and aims to see if the combination leads to a higher rate of complete tumor disappeara…
Phase 3 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:52 UTC